Evidence-based mechanistic reasoning

Journal of the Royal Society of Medicine

Volumn 103, Issue 11, 2010, Pages 433-441

  Howick, Jeremy ^a   Glasziou, Paul ^a   Aronson, Jeffrey K ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; HEPATITIS B VACCINE; PLACEBO;

AIRWAY OBSTRUCTION; CONCEPTUAL FRAMEWORK; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PACKAGING; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; FEEDBACK SYSTEM; GOITER; HEART ARRHYTHMIA; HEPATITIS B; IMMUNIZATION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PHYSICAL PHASE; PROBABILITY; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; REVIEW;

EID: 78349249369     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2010.100146     Document Type: Review

References (61)

1. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd edn. London: Elsevier: Churchill Livingstone, 2005
2. Altman DG. The scandal of poor medical research. BMJ 1994;308:283-4
3. Altman DG. Poor-quality medical research: what can journals do? JAMA 2002;287:2765-7
4. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med 2009;102:186-94
5. Edwards SJ, Lilford RJ, Hewison J. The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals. BMJ 1998;317:1209-12
6. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006;333:1267-9
7. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007;334:349-51
8. Evidence Based MedicineWorking Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992;268:2420-5
9. Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am J Med 2003;114:477-84
10. Bishop JP, Stenger VJ. Retroactive prayer: lots of history, not much mystery, and no science. BMJ 2004;329:1444-6
11. Djulbegovic B, Guyatt GH, Ashcroft RE. Epistemologic inquiries in evidence-based medicine. Cancer Control 2009;16:158-68
12. Evans I, Thornton H, Chalmers I. Testing Treatments: Better Research for Better Healthcare. London: British Library; 2006
13. Lacchetti C, Ioannidis JP, Guyatt G. Surprising results of randomized, controlled trials. In: Guyatt G, Rennie D, eds. The User's Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: AMA Publications; 2002
14. Howick J. Double-blinding: the benefits and risks of being kept in the dark. In: Fennell D ed. Contingency and Dissent in Science Technical Report 03/08. London: Contingency And Dissent in Science Project; 2008
15. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12
16. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5
17. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-62
18. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res 2002;2:18
19. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-12
20. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82
21. Asher R. Apriority: thoughts on treatment. Lancet 1961;2:1403-4
22. Evidence-based policy: where is our theory of evidence? Graduate Conference of the Graduate School for Social Sciences. Milan: Graduate School for Social Sciences; 2007
23. Machamer P, Darden L, Craver CF. Thinking about mechanisms. Philos Sci 2000;67:1-25
24. Grahame-Smith DG, Aronson JK. Oxford Textbook of Clinical Pharmacology. 3rd edn. Oxford: Oxford University Press; 2002
25. Miller FG. Death and organ donation: back to the future. J Med Ethics 2009;35:616-20
26. Miller FG, Truog RD. The incoherence of determining death by neurological criteria: a commentary on "Controversies in the determination of death", a White Paper by the President's Council on Bioethics. Kennedy Inst Ethics J 2009;19:185-93
27. Fisher RA. The design of experiments. 4th edn. Edinburgh: Oliver & Boyd; 1947
28. Popper KR. Conjectures and Refutations: the Growth Of Scientific Knowledge. London: Routledge & K Paul; 1969
29. Freud S, Robert Byck MD, Freud A. Cocaine papers. New York, NY: Stonehill Publ; 1974
30. Kringelbach ML, Aziz TZ. Deep brain stimulation: avoiding the errors of psychosurgery. JAMA 2009;301:1705-7
31. Spock B. [Baby and Child Care.] The Pocket Book of Baby and Child Care, etc. New York, NY: Pocket Books; 1956
32. Ponsonby AL, Dwyer T, Gibbons LE, Cochrane JA, Wang YG. Factors potentiating the risk of sudden infant death syndrome associated with the prone position. N Engl J Med 1993;329:377-82
33. Taylor JA, Krieger JW, Reay DT, Davis RL, Harruff R, Cheney LK. Prone sleep position and the sudden infant death syndrome in King County, Washington: a case-control study. J Pediatr 1996;128:626-30
34. Moore TJ. Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster. New York, NY: Simon & Schuster; 1995
35. Zhang B, Schmidt B. Do we measure the right end points? A systematic review of primary outcomes in recent neonatal randomized clinical trials. J Pediatr 2001;138:76-80
36. Kassai B, Shah NR, Leizorovicza A, Cucherat M, Gueyffier F, Boissel JP. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol 2005;58:1042-51
37. Prentice RL. Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst 2009;101:216-17
38. Hauben M, Aronson JK. Paradoxical reactions: under-recognized adverse effects of drugs. Drug Saf 2006;29:970
39. Waring D. Paradoxical drug response and the placebo effect: a discussion of Grunbaum's definitional scheme. Theor Med Bioeth 2003;24:5-17
40. Howick J. Escaping from placebo prison. BMJ 2009;338:b1898
41. Howick J. Questioning the methodologic superiority of 'placebo' over 'active' controlled trials. Am J Bioeth 2009;9:34-48
42. Bosnak M, Dikici B, Bosnak V, Haspolat K. Accelerated hepatitis B vaccination schedule in childhood. Pediatr Int 2002;44:663-5
43. Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002;20:1157-62
44. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970;1:695-8
45. Howard CR, Young PR, Lee S, et al. Hepatitis B surface antigen polypeptide micelles from antigen expressed in Saccharomyces cerevisiae. J Virol Methods 1986;14:25-35
46. McAleer WJ, Buynak EB, Maigetter RZ,Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178-80
47. Millman I, Eisenstein TK, Blumberg BS. Hepatitis B the virus, the disease and the vaccine. New York, NY: Plenum; 1984
48. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004;103:125-32
49. Lepetic A, Biscayart C, Seigelchifer M, Arduino R, Stamboulian D. Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine. Vaccine 2003;21:4481-5
50. Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009;37:216-21
51. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007;92:3424-8
52. Nielsen VE, Bonnema SJ, Hegedus L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 2006;91:1317-22
53. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
54. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13
55. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-17
56. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12:7-15
57. Simmons D, Upjohn M, Gamble GD. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care 2000;23:153-6
58. Gillies D. Hempelian and Kuhnian approaches in the philosophy of medicine: the Semmelweis case. Stud Hist Philos Biol Biomed Sci 2005;36:159-81
59. Marshall B. Helicobacter connections. ChemMedChem 2006;1:783-802
60. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6
61. Howick J. Oxford Centre for Evidence-Based Medicine Levels of Evidence. Oxford: Centre for Evidence-Based Medicine; 2010